Bupropion hydrobromide and therapeutic applications

Abstract

Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.

1 . A modified release bupropion hydrobromide composition comprising:
 a core comprising a therapeutically effective amount of bupropion hydrobromide; and   a controlled release polymeric coat comprising a water-insoluble polymer and a water-soluble polymer;   wherein said coat at least partially surrounds said core; and   wherein said composition releases bupropion hydrobromide in a first dissolution medium consisting of 0.1 N HCl and 5%-40% v/v ethanol at a rate that is less than or equal to about 1.1 times the rate of release of bupropion hydrobromide from an identical modified release pharmaceutical composition in a second dissolution medium consisting of 0.1 N HCl, measured over a time period of at least from 0 to 2 hours measured using a USP Apparatus I at 75 rpm and at 37±0.5° C.   
     
     
         2 . The modified release composition according to  claim 1  wherein said composition releases bupropion hydrobromide in a first dissolution medium consisting of 0.1 N HCl and 5%-40% v/v ethanol at a rate that is less than or equal to the rate of release of bupropion hydrobromide from the identical modified release composition in a second dissolution medium consisting of 0.1 N HCl. 
     
     
         3 . The modified release composition according to  claim 2  wherein the first dissolution medium consists of 0.1 N HCl and 5% v/v ethanol. 
     
     
         4 . The modified release composition according to  claim 2  wherein the first dissolution medium consists of 0.1 N HCl and 40% v/v ethanol. 
     
     
         5 . The modified release composition according to  claim 1  wherein the time period is from 0 to 16 hours. 
     
     
         6 . The modified release composition according to  claim 1  wherein the composition is a tablet comprising 174 mg, 348 mg or 522 mg of bupropion hydrobromide. 
     
     
         7 . The modified release bupropion hydrobromide composition according to  claim 1  wherein said composition releases bupropion hydrobromide in a dissolution medium consisting of 0.1 N HCl and 40% v/v ethanol at a rate that is less than the rate of release of bupropion hydrochloride from a modified release bupropion hydrochloride composition, in the identical dissolution medium consisting of 0.1 N HCl and 40% v/v ethanol, measured over a time period of at least from 0 to 2 hours measured using a USP Apparatus I at 75 rpm and at 37±0.5° C.;
 wherein the modified release bupropion hydrochloride composition comprises:   a core comprising bupropion hydrochloride, in an amount equimolar to the amount of bupropion hydrobromide in the modified release bupropion hydrobromide composition; and   the identical controlled release polymeric coat comprising a water-insoluble polymer and a water-soluble polymer, used in the bupropion hydrobromide composition; and   wherein the coat at least partially surrounds the core of the modified release bupropion hydrochloride composition.   
     
     
         8 . A method of reducing alcohol-induced dose dumping of bupropion hydrobromide in a patient comprising administering to a patient the modified release pharmaceutical composition of  claim 1 . 
     
     
         9 . The method of  claim 8  wherein the composition is a tablet comprising 174 mg, 348 mg or 522 mg of bupropion hydrobromide.